Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Accenture
McKinsey
US Army
AstraZeneca
Daiichi Sankyo
Merck
Chinese Patent Office
Cantor Fitzgerald

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,260,291

« Back to Dashboard

Summary for Patent: 5,260,291
Title: Tetrazine derivatives
Abstract:[ 3H]-Imidazo[ 5,1-d] -1,2,3,5-tetrazin-4-one derivatives of the formula: ##STR1## wherein R.sup.1 represents hydrogen, or an alkyl, alkenyl or alkynyl group containing up to 6 carbon atoms, each such group being unsubstituted or substituted by from one to three substituents selected from halogen atoms, alkoxy, alkylthio, alkylsulphinyl and alkylsulphonyl groups containing up to 4 carbon atoms, and optionally substituted phenyl groups, or R.sup.1 represents a cycloalkyl group containing from 3 to 8 carbon atoms, and R.sup.2 represents a carbamoyl group optionally N-substituted by one or two groups selected ftom alkyl and alkenyl groups containing up to 4 carbon atoms, and cycloalkyl groups containing 3 to 8 carbon atoms, are new therapeutically useful compounds possessing antineoplastic and immunomodulatory activity.
Inventor(s): Lunt; Edward (Norfolk, GB2), Stevens; Malcolm F. G. (Birmingham, GB2), Stone; Robert (Montrose, AU), Wooldridge; Kenneth R. H. (Lincolnshire, GB2), Newlands; Edward S. (London, GB2)
Assignee: Cancer Research Campaign Technology Limited (London, GB2)
Application Number:07/781,020
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,260,291

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,260,291

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8125791Aug 24, 1981

International Patents Family Members for US Patent 5,260,291

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 380256 ➤ Try a Free Trial
Austria A319182 ➤ Try a Free Trial
Australia 571430 ➤ Try a Free Trial
Australia 5838494 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Cantor Fitzgerald
Merck
McKesson
Medtronic
QuintilesIMS
Teva
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.